Clinical trial
To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors
NCT03159585
Study timeline
Study start (actual)2017-04-14Date precision: day
Registry last updated2020-01-22
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Liver Cancer Stage IVunresolved
Gastric Cancer Stage IVunresolved
Esophageal Cancer, Stage IVunresolved
Bone and Soft Tissue Tumorsunresolved
Breast Cancer Stage IVunresolved
Bladder Carcinoma Stage IVunresolved
Prostate Carcinoma Stage IVunresolved
Thyroid Cancer Stage IVunresolved
Ovarian Cancer Stage IVunresolved
Solid Tumorunresolved
Interventions
TAEST16001DRUG
Sponsors & collaborators
Zhujiang Hospitallead sponsor
Xiangxue Life Science Research Centercollaborator
Xiangxue Pharmaceuticalcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03159585 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.